TLR2 and neoplasm: Thus, combination of antibody-mediated immunotherapy with TLR2 targeting could represent an opportunity to improve NK cell cytotoxicity, which is frequently impaired in HNSCC patients, resulting in enhanced anti-tumor immune responses.